Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Separation or purification
Reexamination Certificate
2005-09-27
2005-09-27
Canella, Karen A. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Separation or purification
C530S414000, C530S416000
Reexamination Certificate
active
06949629
ABSTRACT:
Improved methods are provided for purifying selected carcinoembryonic antigen (CEA) family member proteins. Disclosed method steps include cation-exchange chromatography below pH 4.0 and size-exclusion chromatography, and do not include use of perchloric acid or antibody affinity steps. The resulting purified proteins are of at least 90% purity, substantially free of cross-reacting antigens, substantially free of CA19-9, substantially free of endotoxins, and substantially free of antibodies. Purities of greater than 98% have been achieved. Purified CEA family member proteins used as reference standards, in pharmaceutical carriers, and formulated as vaccines are disclosed. The purification, compositions, and use of CEA family member proteins containing altered immunogenic epitopes are also disclosed.
REFERENCES:
patent: 3867363 (1975-02-01), Hansen
patent: 3956258 (1976-05-01), Hansen
patent: 4086217 (1978-04-01), Hansen
patent: 4140753 (1979-02-01), Edgington et al.
patent: 4145336 (1979-03-01), Edgington et al.
patent: 4180499 (1979-12-01), Hansen
patent: 4180556 (1979-12-01), Kim et al.
patent: 4228236 (1980-10-01), Jakstys et al.
patent: 4272504 (1981-06-01), Kim et al.
patent: 4299815 (1981-11-01), Hansen et al.
patent: 4349528 (1982-09-01), Koprowski et al.
patent: 4471057 (1984-09-01), Koprowski et al.
patent: 4818709 (1989-04-01), Primus et al.
patent: 4863853 (1989-09-01), Bartos et al.
patent: 4871834 (1989-10-01), Matsuoka et al.
patent: 5122599 (1992-06-01), Barnett et al.
patent: 5200316 (1993-04-01), Elting et al.
patent: 5231009 (1993-07-01), Barnett et al.
patent: 5274087 (1993-12-01), Barnett et al.
patent: 5545532 (1996-08-01), Codington et al.
patent: 5571710 (1996-11-01), Barnett et al.
patent: 5672513 (1997-09-01), Terskikh et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5698530 (1997-12-01), Schlom et al.
patent: 5808005 (1998-09-01), Codington et al.
patent: 5837824 (1998-11-01), Bosslet et al.
patent: 5843761 (1998-12-01), Barnett et al.
patent: 6013772 (2000-01-01), Barnett et al.
patent: 6022958 (2000-02-01), Barnett et al.
patent: 6242204 (2001-06-01), Torczynski et al.
patent: 0 102 008 (1983-08-01), None
patent: 0 212 880 (1986-07-01), None
patent: 0 343 946 (1989-05-01), None
patent: 0 346 710 (1989-06-01), None
patent: 0 346 710 (1989-06-01), None
patent: 1 090 927 (1999-10-01), None
patent: WO 84/02983 (1984-08-01), None
patent: WO 95/32286 (1995-11-01), None
patent: WO 99/19478 (1999-04-01), None
patent: WO 01/24832 (2001-04-01), None
patent: WO 01/27159 (2001-04-01), None
patent: WO 01/55337 (2001-08-01), None
Calbiochem 1996-1997 Catalog, 1996, p. 76.
abstract of Hammarstrom (Tumour Biology, 2000, vol. 21, Suppl. 1, p. 42).
Sandy et al (Journal of Biological Chemistry, 1990, vol. 265, pp. 21108-21113).
Pharmacia, Ion Exchange Chromatography, 1991, pp. 7-9.
Aitio, M-L et al., “The electrophoretic heterogeneity of carcinoembryonic antigen,” (1978)Febs Letters93(1):29-32.
Arlen, P. et al., “The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines,” (Jul. 2000)Cancer Immunol. Immunother.49:517-529.
Ashman, L.K. and de Young, N.J., “Immunoadsorbent purification of the carcinoembryonic antigen,” (1977)Immunochemistry14:329-336.
Banjo, C. et al., “Preparation and isolation of immunologically active glycopeptides from carcinoembryonic antigen (CEA),” (1974)Int. J. Cancer13:151-163.
Banjo C. et al., “Intermolecular heterogeneity of the carcinoembryonic antigen,” (1974)Cancer Res.34:2114-2121.
Boenisch, T. and Norgaard-Pedersen, B., “Carcinoembryonic antigen (CEA) of human tissue extracts: partial characterization of two variants separated by affinity chromatography on concanavalin A,” (1975)Clinica Chimica Acta60:51-57.
Carrico, R.J. and Usategui-Gomez, M., “The isolation of carcinoembryonic antigen from tumor tissue at neutral pH,” (1975)Cancer Res.35:2928-2934.
Cho, B.K. et al., “A yeast surface display system for the discovery of ligands that trigger cell activation,” (1998)J. Immunol. Meth.220:179-188.
Chu, T.M. et al., “The reaction between carcinoembryonic antigen and concanavalin A,” (1974)Cancer Res.34:212-214.
Colcher, D. et al., “Differential binding to human mammary and nonmammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen,” (1983)Cancer Investigation1(2):127-138.
Coligan, J.E. et al., “Heterogeneity of the carcinoembryonic antigen,” (1973)Immunochemistry10:591-599.
Coligan, J.E. et al., “Isolation and characterization of carcinoembryonic antigen,” (1972)Immunochemistry9:377-386.
Coligan, J.E. and Slayter, H.S., “Physical, chemical and immunological characterization of saline-extracted, concanavalin A-purified carcinoembryonic antigen,” (1979)Molecular Immunology16:129-135.
Conry, R.M. et al., “Human immune response to carcinoembryonic antigen tumor vaccines,” (1995)J. Immunother.18(2):137, abstract.
Cutler, P., “Size-exclusion chromatography” (1996)Methods in Molecular Biology,S. Doonan, Ed., Humana Press, Totowa, NJ, 255-267.
Duffy, M.J., “Clinical uses of tumor markers: a critical review,” (2001)Critical Reviews in Clin. Lab. Sci.38(3):255-262.
Duraiswami, S. et al., “An evaluation of some methods for the isolation of carcinoembryonic antigen,” (1976)Cancer Related Antigens,P. Franchimont Ed., North-Holland Publishing Co., Amsterdam-New York-Oxford, pp 23-35.
Duraiswami, S. et al., “An improved method for the isolation of carcinoembryonic antigen,” (1976)IRCS Medical Science4:172.
Dykes, P.W. and King, J., “Progress report carcinoembryonic antigen (CEA),” (1972)Gut13:1000-1013.
Egan, M.L. et al., “Physical characterization and structural studies of the carcinoembryonic antigen,” (1976)Cancer Res.35:3482-3485.
Egan, M.L. et al., “Isolation and immunochemical and chemical characterization of carcinoembryonic antigen-like substances in colon lavages of healthy individuals,” (1977)Cancer Res.37:2638-2643.
Eveleigh, J.W., “Heterogeneity of carcinoembryonic antigen,” (1974)Cancer Res.34:2122-2124.
Foon, K.A. et al., “Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine,” (1995)J. Clin. Invest.96:334-342.
Ford, C.H.J. et al., “Immunoadsorbent purification of carcinoembryonic antigen using a monoclonal antibody: a direct comparison with a conventional method,” (1987)Tumor Biol.8:241-250.
Frängsmyr, L. et al., “Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat,” (1999)Tumor Biol.20:277-292.
Fritsche, R. and Mach, J-P, “Isolation and characterization of carcinoembryonic antigen (CEA) extracted from normal human colon mucosa,” (1977)Immunochemistry14:119-127.
Fritz, J.S. and Gjerde, D.T., “Ion Chromatography” (2000) Wiley-VCH Berlang GmbH, Weinheim, Germany, pp. 1-9, 23-27, 50-55, 81-93, 141-164, and 190-191.
Gold, P. and Freedman, S.O., “Specific carcinoembryonic antigens of the human digestive system,” (1965)J. Exp. Med.,122:467-481.
Gold, P. and Goldenberg, N.A., “The carcinoembryonic antigen (CEA): past, present and future,” (1997)McGill Journal of Medicine,3:46-66.
Grunert, F. et al., “Isolation and characterization of two proteins copurifying with carcinoembryonic antigen,” (1984)Tumour Biol.5:221-232.
Hammarström, S., “The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues,” (1999)Cancer Biol.9:67-81.
Hammarström, S. and Baranov, V., “Is there a role for CEA in innate immunity in the colon?” (Mar. 2001)Trends in Micr
Colgin Mark
Landmann Cathy
Newman Diane
AspenBio, Inc.
Canella Karen A.
Greenlee Winner and Sullivan
LandOfFree
Methods for purifying selected CEA family member proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for purifying selected CEA family member proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for purifying selected CEA family member proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446729